2012
DOI: 10.2478/v10127-012-0012-1
|View full text |Cite
|
Sign up to set email alerts
|

Optimal design for population pk/pd models

Abstract: ABSTRACT. We provide some details of the implementation of optimal design algorithm in the PkStaMp library which is intended for constructing optimal sampling schemes for pharmacokinetic (PK) and pharmacodynamic (PD) studies. We discuss different types of approximation of individual Fisher information matrix and describe a user-defined option of the library.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2014
2014
2014
2014

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 14 publications
0
2
0
Order By: Relevance
“…The explicit formula for FIM(β, ξi) using the block diagonal form is given in the Appendix. More information about the derivation of the FIM or other approximations is reported in [27,28,30,[32][33][34].…”
Section: Statistical Methods For Design In Nonlinear Mixed-effects Momentioning
confidence: 99%
“…The explicit formula for FIM(β, ξi) using the block diagonal form is given in the Appendix. More information about the derivation of the FIM or other approximations is reported in [27,28,30,[32][33][34].…”
Section: Statistical Methods For Design In Nonlinear Mixed-effects Momentioning
confidence: 99%
“…An approximation of the expected M F has been proposed for NLMEM, using first order linearisation of the model around the random effect expectation (Mentré et al, 1997;Retout et al, 2002;Bazzoli et al, 2009). This approach has been implemented in several software programs (Bazzoli et al, 2010;Leonov and Aliev, 2012;Gueorguieva et al, 2007;Nyberg et al, 2012) such as PFIM (INSERM, University Paris Diderot), POPED (University of Uppsala), POPDES (University of Manchester), and POPT (University of Otago), frequently used to design new studies in academia as well as in pharmaceutical companies (Mentré et al, 2013).…”
Section: Introductionmentioning
confidence: 99%